Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07450170) titled 'A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China' on Feb. 27.
Study Type: Observational
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Chronic Urticaria
Recruitment Status: Not recruiting
Date of First Enrollment: March 6, 2026
Target Sample Size: 2500
To know more, visit https://clinicaltrials.gov/study/NCT07450170
Published by HT Digital Content Services with permission from Health Daily Digest....